AbbVie Expands Biotech Operations in Puerto Rico

AbbVie is expanding one of its existing sites in Puerto Rico with an estimated investment of $30 million. This expansion will add to PR’s capabilities as a manufacturing destination for biotechnology and is expected to create as many as 100 new jobs during the next two years.
 
The proposed expansion will take place at AbbVie’s site located in the northern municipality of Barceloneta. This site is already home to two of the company’s state-of-the-art facilities. According to Stephen Muldoon, vice president of engineering and operations for AbbVie, the company is focused on providing a significant impact on patients. “This investment demonstrates our commitment to Puerto Rico as a key element of our global manufacturing network. Our presence in Puerto Rico dates to 1969 and our patients benefit from our dedicated and talented local team.”
 
“AbbVie’s expansion in Barceloneta is very important for us, as this site is one of the world’s most advanced biopharmaceutical facilities, contributing to our island’s growing reputation as a biotech hub,” said PR governor Alejandro García Padilla. “AbbVie’s growth plans in Puerto Rico as well as its approach towards innovation and advanced therapies, gives us additional capabilities within the very competitive biopharmaceutical industry. Most important, their $30 million investment to expand their facilities is an encouraging expression of the company’s confidence in their future in Puerto Rico.”